Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis.
Saved in:
| Title: | Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta‐analysis. |
|---|---|
| Authors: | Ferraro, Claire F. (AUTHOR), Stewart, Daniel E. (AUTHOR), Grebely, Jason (AUTHOR), Tran, Lucy T. (AUTHOR), Zhou, Shally (AUTHOR), Puca, Carla (AUTHOR), Hajarizadeh, Behzad (AUTHOR), Larney, Sarah (AUTHOR), Santo, Thomas (AUTHOR), Higgins, Julian P. T. (AUTHOR), Vickerman, Peter (AUTHOR), Degenhardt, Louisa (AUTHOR), Hickman, Matthew (AUTHOR), French, Clare E. (AUTHOR) |
| Source: | Addiction. Jul2021, Vol. 116 Issue 7, p1664-1676. 13p. 3 Diagrams, 2 Charts, 2 Graphs. |
| Subjects: | Therapeutic use of narcotics, Diagnosis of HIV infections, Substance abuse, Meta-analysis, Analgesics, Systematic reviews, Buprenorphine, Medical screening, Methadone hydrochloride |
| Abstract: | Background and aim: Globally, nearly one in five people who inject drugs (PWID) are living with HIV, and the rate of new HIV infections in PWID is increasing in some settings. Early diagnosis is crucial for effective HIV control. We reviewed the evidence on the association between opioid agonist therapy (OAT) and HIV testing uptake among PWID. Methods: We conducted a systematic review searching MEDLINE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials and PsycINFO for studies published from January 2000 to March 2019. Reference lists and conference proceedings were hand‐searched. Observational and intervention studies were eligible for inclusion. Risk of bias was assessed using the Risk of Bias in Non‐Randomised Studies of Interventions (ROBINS‐I) tool. Meta‐analyses were conducted using random‐effects models. Results: Of 13 373 records identified, 11 studies from Australia, Europe, Malaysia and the United States were included. All studies had at least a serious risk of bias, largely due to confounding and selection bias, making it difficult to draw causal conclusions from the evidence. Ten studies provided data on the association between current OAT use and recent HIV testing. Six showed a positive association, while four provided little evidence of an association: pooled odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.28–2.27. Looking at having ever been on OAT and having ever been HIV tested, seven studies showed a positive association and three showed either weak or no evidence of an association: pooled OR = 3.82, 95% CI = 2.96–4.95. Conclusions: Opioid agonist therapy may increase uptake of HIV testing among people who inject drugs, providing further evidence that opioid agonist therapy improves the HIV treatment care cascade. [ABSTRACT FROM AUTHOR] |
| Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background and aim: Globally, nearly one in five people who inject drugs (PWID) are living with HIV, and the rate of new HIV infections in PWID is increasing in some settings. Early diagnosis is crucial for effective HIV control. We reviewed the evidence on the association between opioid agonist therapy (OAT) and HIV testing uptake among PWID. Methods: We conducted a systematic review searching MEDLINE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials and PsycINFO for studies published from January 2000 to March 2019. Reference lists and conference proceedings were hand‐searched. Observational and intervention studies were eligible for inclusion. Risk of bias was assessed using the Risk of Bias in Non‐Randomised Studies of Interventions (ROBINS‐I) tool. Meta‐analyses were conducted using random‐effects models. Results: Of 13 373 records identified, 11 studies from Australia, Europe, Malaysia and the United States were included. All studies had at least a serious risk of bias, largely due to confounding and selection bias, making it difficult to draw causal conclusions from the evidence. Ten studies provided data on the association between current OAT use and recent HIV testing. Six showed a positive association, while four provided little evidence of an association: pooled odds ratio (OR) = 1.71, 95% confidence interval (CI) = 1.28–2.27. Looking at having ever been on OAT and having ever been HIV tested, seven studies showed a positive association and three showed either weak or no evidence of an association: pooled OR = 3.82, 95% CI = 2.96–4.95. Conclusions: Opioid agonist therapy may increase uptake of HIV testing among people who inject drugs, providing further evidence that opioid agonist therapy improves the HIV treatment care cascade. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09652140 |
| DOI: | 10.1111/add.15316 |
